*2.5. Radiologic Response Monitoring and Other Clinical Endpoints*

Tumor size was assessed at weeks 9, 17, 25, and 33, then every 3 months thereafter using magnetic resonance imaging (MRI) with contrast enhancement. Response was evaluated by the Response Evaluation Criteria in Solid Tumors [34] and Immunotherapy Response Assessment in Neuro-Oncology [35] by gadolinium-enhanced T1 weighted images on the basis of the appearance of the pretreatment MRI. Overall survival (OS) was defined by the interval from initial vaccination to date of death. MRI was used to evaluate tumor progression over time.
